758 related articles for article (PubMed ID: 24248265)
1. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
7. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
8. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.
Chaturvedi P; Gilkes DM; Takano N; Semenza GL
Proc Natl Acad Sci U S A; 2014 May; 111(20):E2120-9. PubMed ID: 24799675
[TBL] [Abstract][Full Text] [Related]
10. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition.
Subramanian C; Grogan PT; Wang T; Bazzill J; Zuo A; White PT; Kalidindi A; Kuszynski D; Wang G; Blagg BSJ; Cohen MS
Mol Oncol; 2020 Sep; 14(9):2058-2068. PubMed ID: 32255264
[TBL] [Abstract][Full Text] [Related]
11. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
13. HIF isoforms have divergent effects on invasion, metastasis, metabolism and formation of lipid droplets.
Shah T; Krishnamachary B; Wildes F; Mironchik Y; Kakkad SM; Jacob D; Artemov D; Bhujwalla ZM
Oncotarget; 2015 Sep; 6(29):28104-19. PubMed ID: 26305551
[TBL] [Abstract][Full Text] [Related]
14. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
15. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
16. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
Norton KA; Wallace T; Pandey NB; Popel AS
BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
[TBL] [Abstract][Full Text] [Related]
17. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
[TBL] [Abstract][Full Text] [Related]
18. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
19. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
20. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
